May 1, 2026

Kissei Pharmaceutical Co., Ltd.
(Code 4547, Tokyo Stock Exchange Prime Market)

Licensing Agreement for "Olutasidenib" with Orient EuroPharma in Taiwan

Kissei Pharmaceutical Co., Ltd. (Head Office: Matsumoto City, Nagano Prefecture; Chairman and CEO: Mutsuo Kanzawa; "Kissei") announced that it has entered into a sublicense agreement with Orient EuroPharma Co., Ltd. (Head Office: Taiwan; Chairman: Peter Tsai; "OEP") to license development and commercialization rights in Taiwan for the acute myeloid leukemia (AML) drug "Olutasidenib (generic name)", which is being developed by Rigel Pharmaceuticals, Inc. (Head Office: USA; President and CEO: Raul Rodriguez; "Rigel"), which holds global rights following its acquisition of the program from Forma Therapeutics, Inc.

Under this agreement, OEP will develop and commercialize Olutasidenib in Taiwan. Kissei will receive an upfront payment and milestone payments based on the progress of commercialization in Taiwan, and will supply the formulation to OEP.
OEP has been a long-term partner of Kissei, having licensed our diabetes treatment drug Glufast® in Taiwan.

Olutasidenib works by inhibiting IDH1[*1], which suppresses the inhibition of normal differentiation of stem and progenitor cells and the promotion of neoplastic transformation caused by IDH1 gene mutations, thereby restoring normal cell differentiation. The drug was approved in the United States in December 2022 for the treatment of adult patients with relapsed or refractory AML with a susceptible IDH1 mutation[*2] and is sold by Rigel.

In September 2024, Kissei acquired exclusive development and sales rights for Olutasidenib in Japan, South Korea, and Taiwan from Rigel[1]. We are currently advancing its development domestically.

Kissei is committed to collaborating with partner companies to advance the development of Olutasidenib in regions where rights have been licensed, aiming to provide this drug to patients suffering from relapsed or refractory AML as soon as possible.

The consolidated financial forecast for the fiscal year ending March 31, 2027, incorporating this transaction, is scheduled to be disclosed during the announcement of financial results for the fiscal year ending March 31, 2026, on May 11, 2026.

＜Reference＞

*1: About IDH1 (Isocitrate Dehydrogenase-1)

IDH1 is a cytoplasmic metabolic enzyme that catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) in the citric acid cycle. Mutations in the IDH1 gene are thought to promote DNA methylation, which inhibits normal cell differentiation of stem and progenitor cells and promotes neoplastic transformation.

*2: About IDH1 mutation-positive relapsed/refractory acute myeloid leukemia

Acute myeloid leukemia (AML) is a highly diverse blood malignancy characterized by the autonomous clonal proliferation of immature myeloid cells that have impaired differentiation and maturation ability. As a result of the abnormal proliferation of leukemia cells in the bone marrow, normal hematopoietic function is significantly inhibited, resulting in various symptoms associated with leukopenia, anemia, and thrombocytopenia. If appropriate treatment is not given, it is a serious disease that can become fatal within a short period of time due to infection or bleeding.

Treatment for this disease involves induction therapy, such as the combination of anthracyclines and cytarabine, but 10-40% of patients do not achieve remission[1)], and approximately half of patients relapse[2)], moving on to salvage therapy for relapsed/refractory disease.

The intended indication for this drug is relapsed/refractory AML that is IDH1 mutation-positive, expected to be 5-9% of AML patients[3),4)].

1) Blood (2015) 126 (3): 319-27.
2) Leukaemia Care. Relapse in Acute Myeloid Leukaemia (AML). Version 3.
3) NCCN Guidelines 2024 V3
4) Hou and Tien et. al. Journal of Biomedical Science (2020) 27:81

About Orient EuroPharma Co., Ltd.

Orient EuroPharma Co., Ltd. (OEP) has been developing and marketing pharmaceuticals, nutritional supplements, and beauty-related products based in Taiwan since its establishment in 1982. The company is particularly strong in cancer therapeutics and biologics, and was listed on the Taiwan Stock Exchange in 2003. OEP has expanded its product portfolio through international partnerships and has sales channels not only in Taiwan but also in Southeast Asia and the Chinese market. Since entering into a technology licensing agreement for the diabetes treatment drug Glufast® in Taiwan in December 2005, OEP has maintained a long-term partnership with Kissei. For more information about OEP, please visit their website at https://www.oepgroup.com/en-global.

About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing, and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, please visit their website at https://www.rigel.com.